Syndax to Host R&D Day On July 14 Highlight Late-Stage Revumenib And Axatilimab Programs, Including Ongoing Trials In Idiopathic Pulmonary Fibrosis, Newly Diagnosed Chronic Graft-Versus-Host Disease, And Newly Diagnosed Acute Leukemia

Loading news article.

Syndax to Host R&D Day On July 14 Highlight Late-Stage Revumenib And Axatilimab Programs, Including Ongoing Trials In Idiopathic Pulmonary Fibrosis, Newly Diagnosed Chronic Graft-Versus-Host Disease, And Newly Diagnosed Acute Leukemia | WAPE

Syndax to Host R&D Day On July 14 Highlight Late-Stage Revumenib And Axatilimab Programs, Including Ongoing Trials In Idiopathic Pulmonary Fibrosis, Newly Diagnosed Chronic Graft-Versus-Host Disease, And Newly Diagnosed Acute Leukemia

Article summary

Related companies

Comments —